ABSTRACT
INTRODUCTION
Hepatocellular cancer (HCC) is the fifth most common tumor in the world. It is an important cause of cancer mortality, with approximately one million deaths annually. 1 In the Philippines, HCC is the third leading site of cancer for both sexes. 2 It ranks second among males and 9th among females. In 1998, there were estimated 5,249 new HCC cases (3906 males and 1343 females) and 4,403 deaths. 3 The most common risk factors for HCC include chronic hepatitis B infection, hepatitis C infection, cirrhosis of any etiology, heavy alcohol use and aflatoxin intake. Other authors have implicated smoking as a risk factor 4 while others have argued against this. 5 Hepatocellular carcinoma is more prevalent in the Philippines and Asia because of the increased incidence of Hepatitis B. This also accounts for the younger age of onset of the disease (one to two decades earlier) in these populations. 6 The Philippines is considered a hyperendemic region for Hepatitis B with a 55-68% exposure rate based on serological detection of at least one HBV marker. 3 It is, therefore, expected that Filipino HCC patients will be younger than their Western counterparts.
Characteristics of HCC patients have been described in the literature. However, only a few studies focused on the Filipino population. In 1979, Lacuesta described 30 biopsy-proven hepatoma cases in a tertiary center in Davao according to age and liver function tests. 7 In 1981, Domingo, et al described the typical Filipino HCC patient as male, under 50 years old, and has no recollection of liver disease or exposure to drugs or chemical carcinogens and has no family history of cancer. 8 In 2000, Sollano studied 126 cases in a tertiary hospital. Eighty-seven percent were positive for HBsAg and none tested positive for Hepatitis C. 9 T h e r e i s n o r e c e n t s t u d y d e s c r i b i n g t h e demographics, risk factors and clinical status of patients diagnosed with HCC in the Philippines. Although risk factors for HCC are already established, significance of risk factors may vary among regions, as depicted for example, by the high prevalence of Hepatitis B and HCC in the Philippines compared to other countries. These risk factors may influence the age of onset of the disease, prognosis of patients and screening recommendations for a population. With the recognition of diabetes mellitus as a risk factor for chronic liver disease and hepatocellular carcinoma, it is worthwhile to explore this as another risk factor for HCC among Filipinos. This has not been done in previous studies.
As there are currently no general recommendations to screen for HCC among Filipinos, data on the clinical profile of Filipino HCC patients may lead to new recommendations for screening for HCC and its risk factors among Filipinos.
Research Question
W h a t a r e t h e c l i n i c a l c h a r a c t e r i s t i c s o f hepatocellular cancer patients admitted at the Philippine General Hospital from January 2001 to December 2006?
General Objective
To describe the clinical characteristics of patients diagnosed with hepatocellular cancer admitted at the Philippine General Hospital from January 2001 to December 2006
Specific Objectives
To characterize the clinical and laboratory features of HCC patients at presentation
To describe the hepatitis profile of the HCC patients To determine the proportion of HCC patients with Diabetes Mellitus
MATERIALS AND METHODS

General Study Design
This is a descriptive study, with data collection done through char t review. All char ts with the diagnosis of "hepatocellular carcinoma‰, "hepatoma‰ or "liver cancer‰ admitted within the time period were retrieved from the Medical Records Section of the Philippine General Hospital. In order to increase the yield of cases, we also cross-referenced the Pathology Department database.
Participants
The study included hepatocellular patients admitted from January 2001 to December 2006 diagnosed with HCC either by (1) biopsy or (2) liver mass >2 cm by ultrasound or computed tomographic scan and elevated α-fetoprotein >200. 10 Patients from both charity and pay wards were included. HCC patients from the Out-Patient Department of the institution were not included in the study because charts are not classified according to diagnoses in the Out-Patient Records Section.
Outcome Measures
Demographic data, presenting symptoms and laboratory exams were collated. (See Appendix 1).
Definition of Terms
Cirrhosis-biopsy-proven or nodular liver on imaging (ultrasound or computed tomographic scanning)
Ascites-based on physical examination or documented by imaging
Statistical Analysis
Data collected were encoded in Microsoft Excel. Descriptive statistics (frequencies and percentages) were generated using SPSS 15.0 for Windows.
RESULTS
Demographics
A total of 301 charts were retrieved but only two hundred twenty two patients were included in the study based on our definition of hepatocellular carcinoma. The patients were aged 29 to 86 years old. Mean age was 54 years old. Sixty-five percent were older than 50 years old. Table I compares the young (less than 50 years) and old (greater than or equal to 50 years) subgroups.
Ta b l e I . C o m p a r i s o n B e t w e e n t h e Yo u n g a n d O l d Subpopulations
Characteristics
Young ( Comparison of the patients according to age showed that the younger patients had a higher malefemale ratio of 7.5:1 than the older patients (M: F::2.7:1). A greater proportion of the young patients had chronic hepatitis B (78% vs 42%) while more patients in the old group had past hepatitis B (48% vs 17%). The three patients who had anti-HCV were all older than 50 years. More alcoholic beverage drinkers were found in the young group (30% vs 24%) while the number of smokers was slightly higher in the old group (46% vs 41%). The presence of cirrhosis was equal between the two groups. Males outnumbered females with a sex ratio of 3.5:1. Table II shows the differences between the male and female patients in our population. The female patients were older than the males with mean age of 59 years versus 54 years, respectively. The male patients had a greater proportion with positive HBsAg (53% vs 48%), positive anti-HBc (88% vs 76%), past hepatitis B (41% vs 38%), positive anti-HCV (7.8% vs 0%), alcoholic beverage drinkers (81% vs 16%) and smokers (53% vs 22%). The presence of cirrhosis was also more prevalent among males (38% vs 22%).
Chief Complaint
Chief complaints of the patients on admission are presented in Table III . The most common presenting complaint was abdominal pain, which was the reason for consultation of 57.7%. The second most frequent complaint is a palpable abdominal mass (17.6%). Patients rarely presented with ascites (1.4%) or encephalopathy (1%). Only 1 patient was asymptomatic on admission (0.5%). 
Hepatitis Profile
The availability of a complete hepatitis profile for the patients was variable. Hepatitis B surface antigen (HBsAg) status was only available for 126 patients. Sixty six patients (52.3%) were HBsAg-positive while 60 patients (47.6%) were HBsAg-negative patients. HBeAg, a measure of viral replication and high infectivity, was only positive in seven out of 64 patients (10.9%) with available data. Among the HBsAg-reactive patients, only five patients were HBeAg-positive (12%). However, we should note that 34 patients had no available data on HBeAg status. Overall, there were 66 patients (52.3%) with chronic hepatitis B and 38 patients (40%) with past hepatitis B among those with available test results. Table IV shows the features of HBsAg-positive and HBsAg-negative patients. The HBsAg-negative patients were older (mean 59 years, range 32-83 years) than the HBsAg-positive patients (mean 50 years, range 29-74 years). Majority (63%) of the HBsAg-negative patients were anti-HBc-positive. Another dissimilarity of HBsAg-positive and HBsAg-negative patients was the higher proportion of alcoholic-beverage drinkers (78% vs 69.6%) and smokers (70% vs 38%) in the HBsAg-negative group. Both HBsAg-positive patients (47%) and HBsAg-negative patients (43%) had cirrhosis in less than half of patients. More diabetics were seen in the HBsAg-negative group (20%) than in the HBsAg-positive group (12%).
On the other hand, Hepatitis C infection was examined less frequently. Only 48 patients (21%) were examined for hepatitis C infection. Of these patients, only three (6.2%) were anti-HCV-positive. These three patients were older than 50 years. One of these anti-HCV-positive patients had concomitant chronic hepatitis B infection while another patient had cirrhosis. This cirrhotic patient was a medical doctor, diabetic, heavy alcoholic drinker and smoker.
Alcohol and Smoking
Two-thirds of the population had a histor y of alcoholic ingestion. Moreover, non-alcoholic beverage drinkers, occasional and heavy alcoholic beverage drinkers were almost equal in number. Most alcoholic beverage-drinkers were also smokers (61.5%). However, smokers comprised less than half of the population (45.5%). Approximately one-third had cirrhosis in the patient population (Table V) . Majority of the patients with cirrhosis (69.7%) and without cirrhosis (69.2%) were older than 50 years. The mean age in the cirrhotic and noncirrhotic group was almost the same (54 and 55 years, respectively). The proportion of HBsAg-positive patients was the slightly higher in the cirrhotic (54%) than the noncirrhotic subset (50%). In contrast, more noncirrhotic patients (16.6%) had positive HBeAg status than cirrhotics (5.8%). The number of patients with past hepatitis B was slightly greater in the noncirrhotic group (42% vs 35%). Fewer patients had a history of alcoholic beverage drinking in the noncirrhotic group (62% vs 75%). More smokers were found among patients with cirrhosis (51%) than in those without cirrhosis (42%). Diabetes mellitus was observed in 18% of patients with cirrhosis and 11% of patients without cirrhosis. Notable differences in the laboratory exams included greater prevalence of elevated aspartate aminotranferase (94% vs 89%) and hyperbilirubinemia (40% vs 33%) among the cirrhotic patients.
Cirrhosis
Comorbidities
Most patients (68%) had no confounding illness. The most common comorbidity was hypertension, occurring in 14% of the study population. This was followed by diabetes mellitus with 13.5% prevalence in our study population. Other comorbidities noted were pulmonar y tuberculosis (2.3%), bronchial asthma (2.3%), breast cancer (0.9%) and chronic kidney disease.
Laboratory Exams
Of 105 patients with available data bilirubin levels, thirty three (31.4%) had elevated levels. Eighty one of 131 patients with available results had hypoalbuminemia. Majority had normal protime (77%) and platelet count (58%) results. Measures of liver damage were increased in our patients. One hundred twenty of 132 (91%) had elevated aspartate aminotransferase and 88 of 156 (56.4% ) had elevated alanine aminotransferase values.
Staging and Treatment
On staging by Barcelona Clinic Liver Cancer Classification, 87.8% were in the advanced stage and 11.7% were terminal stage.
Eighty percent of patients did not undergo any inter vention for their condition. The most common modalities employed were resection of the hepatic mass (done in 17 patients) and transar terial chemoembolization (done in 16 patients). Other treatments implemented were chemotherapy, tamoxifen and alcohol injection. Different combinations of these were also applied in other patients.
DISCUSSION
Majority of our patients were older than 50 years old. This is in contrast to the findings of the two Filipino studies by Domingo (1981) and Lacuesta (1979) where most patients were younger than 50. The age distribution is more similar to recent studies abroad. Motola-Kuba 11 and Kim et al 1 reported a peak incidence among the 65-69 years of age and 6th decade of life, respectively. Wong and Tsai 12 described the mean age at 60 among Filipinos in their United States Study. This shift in the maximum age of occurrence from the young to the old may reflect differences in risk factors and utility of preventive measures such as the Hepatitis B vaccine which was initially implemented in 1980 in the Philippines. However, data on the use of Hepatitis B vaccine by patients in our study could not be obtained through our methodology. Important differences noted between the young and older patients in our study were the presence of chronic hepatitis B and past hepatitis B. The older patients had a greater proportion of past hepatitis B (HBsAg-negative/antiHBc-positive) while the younger patients had chronic hepatitis B. This is similar to other report. 1, 13 No patient in the young group had hepatitis C, but this can be because Hepatitis C was quite infrequent in our study population.
The male predominance of the population in this study is consistent with previous literature. The sex ratio of 3.5:1 is lower than the previously reported ratio of 5:1 to 6:1 by Domingo. 8 It is again more comparable to recent reports. A male-female ratio of 2-4:1 is described by Bosch, et al 14 in Mexico and a ratio of 1.6:1 by Chen, et al 15 in Taiwan. The reasons for the disparity between men and women are obscure, but they may include environmental factors such as a higher prevalence of persistent HBV or HCV infection, alcohol abuse and smoking in men than in women 16 as seen in our study population. Genetic and hormonal factors may also be important, as has been underscored in a recent study by Naugler, et al. 17 Men have an increased risk for HCC even when young while the risk increases with age in women. However, our study has a selection bias because only admitted patients were included in the study. Women generally seek consult more and HCC cases in women may have been diagnosed in the earlier stages and thus, may not necessitate admission.
Chronic hepatitis B is the strongest risk factor for HCC in Asians and Filipinos. Sixty six patients in our study had chronic hepatitis B. This may be an underestimate because of the unavailability of data for 96 patients. An important mode of transmission of chronic hepatitis B in the Philippines is through vertical transmission. In 1984, Tiangco-Torres et al. examined 533 pregnant and puerperal women and found that HBV exposure rate was 59.7% and HBsAg-positivity rate was 9.2%. Of the HBsAg positive women, 20.7% also had HBeAg and 62.1% had anti-HBe. Based on these data, it is estimated that 27,600 neonates from 1.5 million live births per year in this country will get maternally transmitted HBV infection. 18 Hepatitis C infection is another well recognized risk factor for HCC. It is the most common chronic bloodborne infection and is endemic worldwide. Local data, however, showed varying rates of 17%, 36%, 12.9%, 35% and 11% among pediatric patients with chronic liver disease, hemodialysis, homosexuals, parenteral drug users and blood donors, respectively. 3 Mappala reported a prevalence rate of 8.8% among cirrhotics and 94.4% among cirrhotics wih HCC. 19 HCV infection was detected uncommonly in our study population, appearing in only three patients. Mechanism of carcinogenesis of HCV remains unclear because HCV does not incorporate its genome into the host genetic material. Repeated cycles of regeneration and repair in cirrhosis may lead to mutant strains of the virus. 6 Only one of three anti-HCV-positive patients had cirrhosis in our population. But due to the small number of anti-HCV positives, it will be inaccurate to generalize that HCV does not lead commonly to cirrhosis in HCC patients.
Cir rhosis is a strong risk factor for HCC, irrespective of the etiology. The annual risk of developing HCC among patients with cirrhosis is 1-6%. 20 However, almost two-thirds of our patients had no cirrhosis. In addition, the difference between the cirrhotics and noncirrhotics based on HBsAgpositivity was not large (54% vs 50%). This is probably because the pathogenesis of HBV infection leading to HCC does not require the development of cirrhosis. Chiesa found an odds ratio of 17.6 and 20.3 for HBsAg-carriers in the presence and absence of cirrhosis, respectively. 21 It has been well established that integrated HBV DNA may account for the hepatocarcinogenesis in chronic HBV carriers and in the presence of HBeAg, the surrogate marker for the presence of HBV DNA, HCC is seen more frequently among HBsAg-carriers. In a study by Yang, the relative risk of hepatocellular carcinoma was 9.6 (95% confidence interval, 6.0 to 15.2) among men who were positive for HBsAg alone and 60.2 (95% confidence interval, 5.5 to 102.1) among those who were positive for both HBsAg and HBeAg, as compared with men who were negative for both. 22 We regret that HBV DNA levels were not documented in our patients but fortunately, HBeAg was tested. A higher proportion of patients were positive for HBeAg in the noncirrhotic group compared to the cirrhotic group, accounting for some of the HCC cases.
However, HBeAg was still quite uncommon in our patients, occurring in only 12% of those tested. This is comparable to Chen, et alÊs study in 2006. 15 They found that there was a dose-response relationship between cumulative hepatocellular carcinoma incidence and serum HBV DNA level for a subcohort who were seronegative for HBeAg, had a normal ALT level, and did not have liver cirrhosis, which included most participants (80%). Most participants seronegative for HBeAg (72.0%) still had a detectable serum HBV DNA. This suggests that HBV DNA levels should be determined in patients with HBsAg regardless of HBeAg status and presence or absence of cirrhosis because they may be at risk for HCC depending on HBV DNA levels.
A notable variation between the cirrhotic and noncirrhotic group is the presence of antibody against the hepatitis B core antigen in HBsAg-negative patients. More patients with noncirrhotic livers had positive anti-HBc in the subset of HBsAg-negative patients (previous hepatitis B infection). Previous hepatitis B infection is a less well known risk factor for HCC. When Uetake studied 91 patients with HBsAgnegative and anti-HCV-negative alcoholic cirrhosis, he found that the occurrence rate of HCC in patients with anti-HBc and without anti-HBc were 15.6% and 2.9%, respectively, at the 5th year of observation. 23 In 2002, Yano compared HCC patients with past hepatitis B to HCC patients with chronic hepatitis B. A significant difference between the two groups was that patients with past hepatitis B were older (72.1 years old) at diagnosis than patients with chronic hepatitis B (56.2 years old). 24 This is parallel to our findings. These HBsAg-negative/anti-HBc-positive patients either had acute hepatitis B or had delayed natural clearance of HBsAg among chronic HBV carriers. It is also possible that deletion, mutation, or rearrangement in the HBV surface gene may cause the serum HBsAg to become seronegative. However, it has been generally accepted that chronic HBV carriers are usually infected in infancy or early childhood as a result of vertical or horizontal spread, and HBsAg persists in carriers for a long time. Conversely, those infected with HBV during adulthood usually clear HBsAg from their sera. This explains the older age of development of HCC in patients who clear the HBsAg from their sera. Thus, the risk of HCC persists in long-term HBV carriers from Asia who lose HBsAg, and these patients should continue to undergo surveillance. 25 Among our patients with and without cirrhosis, an increased prevalence of diabetes mellitus (DM) was noted. It was observed in 13.5% of the HCC patients: in 18% of the patients with cirrhosis and in 11% of the patients without cirrhosis. Furthermore, DM was observed in 20% of HBsAg-negative patients and in 12% of HBsAg-positive patients. These rates are more than double the national prevalence of DM of 4.0%. 26 Diabetes Mellitus is an implicated risk factor in HCC recently. Subjects with a history of diabetes had an OR of 2.7 (95% CI, 1.6 4.3) for HCC compared with nondiabetic subjects in a United States study. In this study, a synergistic interaction on HCC risk was observed between heavy alcohol consumption and diabetes (OR =4.2; 95% CI, 2.6 5.8), and between diabetes and viral hepatitis (OR =4.8; 95% CI, 2.7 6.9). 27 A number of possible mechanisms might explain this association. First, since most case subjects with diabetes are non-insulin dependent and are characterized by hyperinsulinemia, insulin or its precursors may interact with liver cells to stimulate mitogenesis or carcinogenesis. The substantial reduction in IGF-I and IGFBP-3 levels among diabetic, as compared with nondiabetic, HCC case subjects in a study by Lagiou, et al may reflect an intimate link between pancreatic and hepatocellular processes, the nature of which are poorly understood. 28 Alternatively, the metabolic effects of diabetes may increase the risk of HCC through nonalcoholic steatohepatitis and cryptogenic cirrhosis.
Nonalcoholic steatohepatitis may also be a risk factor for HCC. Marrero suggested that the underlying liver disease in 13% of their patients with HCC may be due to nonalcoholic steatohepatitis. 29 Hypertension, a component of Metabolic Syndrome linked to nonalcoholic steatohepatitis, was fairly common among our HCC patients. But this may be reflective of the prevalence of hypertension in the Philippines which is around 17%. 26 Other components of the metabolic syndrome such as body mass index, waist to hip ratio and dyslipidemia should be explored if related to hepatocellular carcinoma among Filipinos. 31 But then again, we recognize that our study population is skewed because of an admission rate bias inherent in our inclusion criteria.
Limitations
Our studyÊs limitations stem primarily from our methodology. Since the data collection was done through chart review, completeness of data was not controlled by the investigators. Thus, pertinent data such as occupation, exposures to the blood-borne viruses Hepatitis B and C, immunization history, family history, full hepatitis panel, height, weight and lipid profile were not obtained. It would have been more comprehensive to incorporate data of patients seen in the clinics. We could have seen patients that belonged to earlier stages of the disease unlike our inpatients. 
CONCLUSION
